Your Location：Home >Products >Pharmaceutical >1257044-40-8

1257044-40-8

  • Product Name:ABT-199
  • Molecular Formula:C45H50ClN7O7S
Inquiry

Product Details

Purity:99%

ABT-199 Cas No.1257044-40-8 In Medicine with Wholesale Price

1257044-40-8 Name

Name

ABT-199

Synonym

 ABT-199;ABT-199 (GDC-0199);GDC-0199;ABT-199 100MG;2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)met;ABT-199, Venetoclax;ABT-199 (GDC-0199)Venetoclax;4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]ami;Venclexta

 

 

1257044-40-8 Chemical & Physical Properties

Density

1.3±0.1 g/cm3

Molecular Formula

C45H50ClN7O7S

Molecular Weight

868.439

PSA

186.58000

LogP

10.88

Exact Mass

867.318115

Index of Refraction

1.644

Water Solubility

Insuluble (6.3E-6 g/L) (25 ºC)

ABT-199 Cas No.1257044-40-8 In Medicine Usage

ABT-199, also known as venetoclax, is a small, oral chemical molecule used for the treatment of chronic lymphocytic leukemia (CLL) associated with a specific chromosomal abnormality. As a second line treatment drug of CLL, ABT-199 take effects through acting as a BH3-mimetic and inhibitor of Bcl-2 (the anti-apoptotic B-cell lymphoma-2protein), further inducing apoptosis of CLL cells but not platelets. It also has the potential for the treatment of ER-positive breast cancer. As a specific Bcl-2 inhibitor of Bcl-2, ABT-199 was approved by FDA to treat CLL in 2015.

ABT-199 1257044-40-8 Relevant articles

A PROCESS FOR THE PREPARATION OF VENETOCLAX AND ITS POLYMORPHS THEREOF

-

, (2021/02/12)

The present invention relates to a process for the preparation of 4-(4-{[2-(4-chlorophenyl)-4,4dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b] pyridin-5-yloxy)benzamide) compound of formula-1 which is represented by the following structural formula: Formula-1.

IFN-γ enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway

Xiaoya Shao,Xueqiong Meng,Haiping Yang,Xinxin Wang,Ling Qin,Guomin ShenORCID Icon,Xiaoping Xi,Huijuan Zhao,Salvador Macip &Yixiang Chen

Leukemia & Lymphoma Volume 64, 2023 - Issue 1

The combination of ABT-199 with JAK1/2 inhibitor Ruxolitinib or STAT3 inhibitors Stattic and C188-9 increased malignant B cell death, thus blocking this pathway with inhibitors increased ABT-199 efficiency to induce CLL cell apoptosis, suggesting a potential therapeutically relevant combination to overcome ABT-199 resistance.

1257044-40-8 Process route

C<sub>52</sub>H<sub>56</sub>ClN<sub>7</sub>O<sub>9</sub>S<sub>2</sub>

C52H56ClN7O9S2

2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide
1257044-40-8

2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide

Conditions
Conditions Yield
With lithium hydroxide; In methanol; at 20 - 68 ℃;
90%
C<sub>51</sub>H<sub>53</sub>ClN<sub>8</sub>O<sub>11</sub>S<sub>2</sub>

C51H53ClN8O11S2

2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide
1257044-40-8

2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide

Conditions
Conditions Yield
With caesium carbonate; In isopropyl alcohol; at 20 - 80 ℃;
92%

1257044-40-8 Upstream products

  • 1228779-96-1
    1228779-96-1

    3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide

  • 1235865-77-6
    1235865-77-6

    [2-((1H-pyrrolo [2,3-b]pyridin-5-yl)oxy)-4-(4-((4’-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1’-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid]

  • 130290-79-8
    130290-79-8

    4-tetrahydropyranmethylamine

  • 406233-31-6
    406233-31-6

    4-fluoro-3-nitrobenzenesulfonamide

1257044-40-8 Downstream products

  • 1379647-80-9
    1379647-80-9

    4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide sulfate

Relevant Products

  • Friend Links:
  • Tel: 0086-21-56469616 Fax: Email: minstar@minstargroup.com
  • Address: BUILDING 8, NO.1098, CHUANSHA ROAD, PUDONG, SHANGHAI, CHINA
Copyright @2009-2024 SHANGHAI MINSTAR CHEMICAL CO., LTD.